Hagop Kantarjian, Professor of Department of Leukemia at MD Anderson Cancer Center, shared a post on X:
“Adding blinatumomab and inotuzumab to hyperCVAD in younger B-cell ALL improves EFS from 66% to 89%.”
Title: Hyper-CVAD Versus Hyper-CVAD Plus Blinatumomab With or Without Inotuzumab Ozogamicin for Adult Patients With Newly Diagnosed Philadelphia Chromosome-Negative Acute Lymphoblastic Leukemia: A Propensity-Score Analysis
Authors: Elias Jabbour, Hannah Goulart, Koji Sasaki, Caitlin R. Rausch, Nitin Jain, Tapan M. Kadia, Courtney DiNardo, Naval Daver, Naveen Pemmaraju, Farhad Ravandi, Guillermo Montalban-Bravo, Guillermo Garcia-Manero, Danielle Hammond, Mahesh Swaminathan, Maria Hachem, Rita Khouri, Maro Ohanian, Rebecca Garris, Nicholas J. Short, Hagop M. Kantarjian
Other articles featuring Hagop Kantarjian on OncoDaily.